A new generation of cancer vaccines
Using its novel synthetic DNA vaccine technology, Inovio has created the potential for a new generation of cancer vaccines. This technology enables us to design synthetic vaccines that target multiple antigens of the disease, with the genetic makeup of the antigen based on different strains of the cancer to help break the body’s tolerance against cancerous cells
We have developed SynCon® vaccines to treat a variety of cancers, including cervical dysplasia/cancer, which is in a phase II clinical study, and prostate cancer. We are also collaborating on DNA vaccine programs to treat acute and chronic myeloid leukemia (AML and CML) and multiple cancers that express the antigen called hTERT.
Page 'Breadcrumb' Navigation